Transaction DateRecipientSharesTypePriceValue
22nd January 2021Rita Jain20,000Grant/award etc.$0.00
21st December 2020Steven C Gilman4,000Open or private purchase$6.25$25,000.00
23rd October 2020Scott A Canute13,516Sale back to the issuer$0.00
1st October 2020Steven C Gilman7,796Sale back to the issuer$0.00
11th August 2020Michael Thomas Heffernan13,071Open or private sale$19.13$250,048.23
5th August 2020Steven C Gilman13,000Exercise of derivative$10.63$138,190.00
5th August 2020Steven C Gilman13,000Open or private sale$32.75$425,750.00
29th July 2020Steven C Gilman10,000Open or private sale$29.70$297,000.00
29th July 2020Steven C Gilman10,000Exercise of derivative$10.63$106,300.00
22nd July 2020Steven C Gilman10,000Grant/award etc.$10.63$106,300.00
Akebia Therapeutics
Akebia Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.

Akebia Therapeutics, Inc. is a biopharmaceutical company. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat.

Ticker: AKBA
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1517022
Employees: 360
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $245 M (0%)
Inventory, Net: $105 M (0%)
Assets, Current: $449 M (45%)
Property, Plant and Equipment, Net: $9 M (0%)
Other Assets, Noncurrent: $47 M (-37%)
Assets: $745 M (-3%)
Accounts Payable, Current: $29 M (-24%)
Accrued Liabilities, Current: $143 M (0%)
Liabilities, Current: $196 M (-5%)
Long-term Debt, Excluding Current Maturities: $76 M (0%)
Other Liabilities, Noncurrent: $42 M (37%)
Liabilities: $375 M (0%)
Common Stock, Value, Issued: $1 Th (0%)
Common Stock, Shares, Issued: $143 M (0%)
Additional Paid in Capital, Common Stock: $1 B (17%)
Retained Earnings (Accumulated Deficit): $1 B (29%)
Stockholders' Equity (Parent): $370 M (0%)
Liabilities and Equity: $745 M (-3%)
Revenue: $90 M (-49%)
Research and Development: $53 M (-60%)
Operating Income/Loss: $174 M (-25%)